Acumen pharmaceuticals, inc. and halozyme enter global collaboration and license agreement to develop subcutaneous formulation of acu193 with enhanze® technology

Expect to initiate phase 1 development in mid-2024 to compare pharmacokinetics of subcutaneous form to intravenous form of acu193 expect to initiate phase 1 development in mid-2024 to compare pharmacokinetics of subcutaneous form to intravenous form of acu193
ABOS Ratings Summary
ABOS Quant Ranking